Stockscreener 앱 받기
1.22
6.15%
-0.08
전일 마감가:
$1.30
열려 있는:
$1.27
하루 거래량:
591.30K
Relative Volume:
0.16
시가총액:
$54.64M
수익:
-
순이익/손실:
$-51.50M
주가수익비율:
-0.305
EPS:
-4
순현금흐름:
$-47.10M
1주 성능:
-8.26%
1개월 성능:
+15.10%
6개월 성능:
-21.28%
1년 성능:
-79.87%
1일 변동 폭
$1.22
$1.30
1주일 범위
$1.22
$1.33
52주 변동 폭
$0.79
$6.98
아웃룩 테라퓨틱스 Stock (OTLK) Company Profile
명칭
Outlook Therapeutics Inc
전화
(609) 619-3990
주소
111 S. WOOD AVENUE, ISELIN, NJ
OTLK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.23 | 57.75M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.04 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
627.25 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.36 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
830.00 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.91 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
아웃룩 테라퓨틱스 Stock (OTLK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-27 | 업그레이드 | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-13 | 개시 | CapitalOne | Overweight |
| 2023-04-03 | 개시 | Guggenheim | Buy |
| 2023-02-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 개시 | BTIG Research | Buy |
| 2022-09-13 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2019-05-16 | 개시 | Oppenheimer | Outperform |
| 2019-04-22 | 개시 | Ascendiant Capital Markets | Buy |
모두보기
아웃룩 테라퓨틱스 주식(OTLK)의 최신 뉴스
Will Outlook Therapeutics Inc. (41ON) stock enhance shareholder valueJuly 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
Can Outlook Therapeutics Inc. stock beat analyst upgradesEarnings Miss & AI Forecast Swing Trade Picks - newser.com
Is Outlook Therapeutics Inc. (41ON) stock worth buying before Fed actionMarket Movement Recap & Smart Investment Allocation Tips - newser.com
How Outlook Therapeutics Inc. stock reacts to Fed rate cutsProfit Target & Stepwise Entry/Exit Trade Alerts - newser.com
Outlook Therapeutics Inc. stock momentum explainedIndex Update & Free Growth Oriented Trading Recommendations - newser.com
Will Outlook Therapeutics Inc. (41ON) stock outperform value peersPortfolio Growth Summary & Intraday High Probability Setup Alerts - newser.com
Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 - TradingView
[8-K] Outlook Therapeutics, Inc. Reports Material Event | OTLK SEC FilingForm 8-K - Stock Titan
Outlook Therapeutics, Inc. Re-Submits Biologics License Application for ONS-5010 - MarketScreener
Outlook Therapeutics (OTLK) Re-Submits BLA for Key Eye Treatment - GuruFocus
Outlook Therapeutics resubmits BLA for wet AMD treatment - Investing.com
How Outlook Therapeutics Inc. (41ON) stock compares with tech leadersQuarterly Profit Review & Stock Portfolio Risk Control - newser.com
Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 to FDA for Wet AMD Treatment - Quiver Quantitative
Outlook Therapeutics Inc. stock prediction for this weekBond Market & Capital Efficiency Focused Ideas - newser.com
Outlook Therapeutics (Nasdaq: OTLK) re-submits BLA for LYTENAVA in wet AMD - Stock Titan
Is Outlook Therapeutics Inc. stock a smart buy before Fed meetingWeekly Volume Report & Weekly Market Pulse Updates - newser.com
Is Outlook Therapeutics Inc. stock cheap at current valuationTrade Risk Report & Daily Price Action Insights - newser.com
What earnings margins imply for Outlook Therapeutics Inc. (41O) stockMarket Rally & Long-Term Growth Stock Strategies - newser.com
Full technical analysis of Outlook Therapeutics Inc. stockQuarterly Trade Summary & Advanced Swing Trade Entry Alerts - newser.com
Why analysts upgrade Outlook Therapeutics Inc. stockForecast Cut & Technical Pattern Recognition Alerts - newser.com
Is Outlook Therapeutics Inc. (41O) stock bottoming after sell offTrade Volume Summary & Daily Chart Pattern Signals - newser.com
How to read the order book for Outlook Therapeutics Inc.Earnings Beat & Intraday High Probability Alerts - newser.com
Is Outlook Therapeutics Inc. stock a dividend growth opportunityEarnings Performance Report & Risk Controlled Stock Pick Alerts - newser.com
What technical models suggest about Outlook Therapeutics Inc.’s comebackWeekly Gains Summary & Real-Time Volume Spike Alerts - newser.com
What analysts say about Outlook Therapeutics Inc 41O stockResistance Zone Identification & Low Cost Wealth Strategies - earlytimes.in
Weiss Ratings Reiterates "Sell (D-)" Rating for Oncobiologics (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics Inc. stock chart pattern explainedMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
What drives Chordate Medical Holding AB publ K1Z0 stock priceFlag and Pennant Patterns & Market Crushing Stock Picks - earlytimes.in
아웃룩 테라퓨틱스 (OTLK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.56%
자본화:
|
볼륨(24시간):